Why Sampling Time Is Part of DDI Study Design
A concentration-time profile is observed only at the times when samples are collected. A schedule that misses the absorption peak can miss the highest measured concentration, and one that stops too early may not describe the later exposure adequately. These risks matter in a drug-drug interaction (DDI) study because a perpetrator can change the height, timing, or decline of a victim drug’s profile. Scheduling therefore needs to anticipate the relevant phases in both the control condition and the perpetrator condition.
The goal is not to guess every concentration in advance. It is to use the expected pharmacokinetics, dose and route to put samples where they are informative, then preserve enough coverage to detect a profile that differs from expectation. For an oral probe, this usually means relatively close spacing around the expected absorption peak and follow-up through the elimination phase. For an intravenous (IV) probe, sampling must be anchored to the administration itself: a bolus calls for very early samples, while an infusion calls for samples during and immediately after infusion as well as later samples.
Design Principles and Assumptions
Start by specifying the event that defines time zero: for example, the start of an oral dose or the start of an IV infusion. Record actual administration times as well as planned times, since deviations can otherwise make samples appear to occur at the wrong pharmacokinetic phase. Use established information about the probe, formulation, dose, food conditions, and route to set a plausible window for absorption, peak concentration, distribution, and elimination.
The schedule should not be based on a single exact prediction of \(T_{\max}\). Instead, define a plausible peak window and sample more closely within it. The window should account for known variability and for a possible shift in the perpetrator condition. Samples before and after the expected peak help establish whether the profile is rising or falling around its maximum. Samples later in the profile help characterize the decline and contribute to exposure over the chosen observation interval.
A useful local justification for denser peak sampling follows from a smooth-profile assumption. Suppose \(C(t)\) has a differentiable local maximum at time \(t^*\), so \(C'(t^*)=0\), and its second derivative is bounded in magnitude by \(K\) near that maximum. Taylor’s theorem gives, for a nearby sample time \(t^*+\delta\),
Thus, under these local conditions, reducing the distance \(|\delta|\) between the true peak and a sample limits the possible difference between the sampled concentration and the peak, with the bound shrinking in proportion to the squared distance. This does not guarantee an exact observed \(C_{\max}\): the true peak time is not known in advance, and real profiles may not be smooth or have a single peak. It explains why close spacing across a plausible peak window is preferable to relying on one sample at a predicted peak time.
For the elimination phase, a simple first-order terminal decline gives a planning aid. If the terminal half-life is \(t_{1/2}\), concentration after the terminal phase begins is proportional to \(2^{-t/t_{1/2}}\), where \(t\) is elapsed time in that phase. This is an assumption for planning, not proof that the observed profile follows a single exponential throughout. A schedule should extend long enough to observe meaningful decline and should be checked against available information about the probe’s half-life and the study’s intended exposure interval.
Worked Scheduling Examples
Worked Example: Oral Probe With a Possible Peak-Time Shift
Suppose a hypothetical oral probe is expected to reach its peak between 1 and 2 hours in the control condition. Based on the planned perpetrator and prior pharmacokinetic knowledge, the peak could occur as late as 3 hours during coadministration. The terminal half-life is approximately 6 hours, and the intended profile follow-up is 24 hours after dosing. Construct a schedule that covers the peak window and the later profile.
Use a predose sample and the following postdose times: 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 4, 6, 8, 12, and 24 hours. The times from 0.25 through 3 hours provide close coverage across the plausible peak window in both conditions; the schedule does not depend on the peak occurring at precisely 1.5 hours. The later samples provide a description of the decline through 24 hours.
For a rough terminal-coverage check, if the terminal half-life is 6 hours, then 24 hours corresponds to \(24/6=4\) half-lives. Under the assumed first-order terminal decline, the remaining fraction after four half-lives is \(2^{-4}=1/16=0.0625\), or 6.25% of the concentration at the start of that terminal phase. This calculation supports 24 hours as a plausible follow-up point for this hypothetical plan, but it does not establish that absorption is complete by then or that the terminal phase starts at dose time.
Use the same planned postdose times in control and perpetrator periods. If the perpetrator delays the peak, the 2.5- and 3-hour samples still cover the later part of the expected peak region; if it does not, the earlier samples provide peak-region observations in the control-like profile. This schedule is a design proposal, not a guarantee that every individual peak will fall between sampled times.
Worked Example: IV Infusion and the Infusion-End Sample
Consider a hypothetical probe administered as a 30-minute infusion beginning at time zero. A proposed 0.25-hour sample is during the infusion, because \(0.25\) hours is 15 minutes. The infusion ends at \(30/60=0.5\) hours, so the end-of-infusion sample belongs at 0.5 hours. A schedule could include predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, and 12 hours.
Suppose hypothetical concentrations are 0 mg/L predose, 5 mg/L at 0.25 hours, 12 mg/L at 0.5 hours, 9 mg/L at 0.75 hours, 6 mg/L at 1 hour, and lower at each later sample. Among these sampled values, the observed maximum is 12 mg/L at 0.5 hours, the end of infusion. The 0.25-hour result is not an end-of-infusion concentration: it was obtained halfway through the 30-minute infusion. Samples immediately after infusion help show the early decline, while later samples describe subsequent elimination.
This schedule assumes the infusion duration and start time are controlled and that these time points are feasible. If the perpetrator could alter the early profile, retaining early and end-of-infusion samples in both conditions is important. If the IV administration were a bolus instead, the infusion-specific 0.5-hour anchor would not apply; samples would generally need to be concentrated at much earlier times after injection to characterize rapid distribution.
Worked Example: IV Bolus With Rapid Early Distribution
A hypothetical IV bolus probe is expected to show a steep concentration decline during the first hour, followed by a slower terminal decline. A schedule beginning at 1 hour would miss much of the early profile. One possible schedule is predose, 0.05, 0.1, 0.25, 0.5, 0.75, 1, 2, 4, 8, and 12 hours after the bolus.
Convert the first times to minutes to check their placement: \(0.05\times60=3\) minutes and \(0.1\times60=6\) minutes. These early draws are intended to capture rapid changes immediately after administration; the 0.25-, 0.5-, and 0.75-hour samples continue coverage through the first hour. The later times extend follow-up into the slower decline. The exact early times must be checked against administration and sample-processing feasibility; a nominal 3-minute draw is unhelpful if the site cannot collect it reliably.
Apply the same time definitions and planned times in the control and perpetrator conditions. If early concentrations are expected to change substantially between adjacent samples, the schedule may need even closer early spacing, provided it is operationally feasible. If observed concentrations are still changing rapidly at 12 hours, the planned follow-up is not adequate to characterize the later profile and should be reconsidered.
Keeping Conditions Comparable and Checking the Schedule
For a within-subject DDI comparison, schedule samples relative to the victim dose or IV administration in each condition, and keep the nominal times and collection procedures comparable. Perpetrator dosing must also be timed according to the intended interaction state; the earlier material on aligning victim dosing with pharmacokinetic sampling addresses that timing relationship. A changed concentration profile is interpretable only if sample timing is understood in relation to both drug administrations.
Do not assume that matching nominal times means every sample reflects the same phase in both conditions. A perpetrator may shift the peak or change the decline. That is why a robust plan covers a range of plausible peak times and includes later samples, rather than sampling only at one predicted maximum. Record actual times so departures from the schedule can be evaluated.
Before finalizing a schedule, check whether the number and timing of samples are workable for participants and the clinical site. Closely spaced draws may be informative but burdensome; an impractical schedule can produce missed or mistimed samples. Confirm that early draws are feasible, the end of an infusion is explicitly represented when relevant, and follow-up extends far enough for the intended profile. Review pilot or prior data, if available, to see whether observed peaks or declines fall outside the planned windows.
Alternatives, Limitations, and Common Pitfalls
| Approach | Strength | Limitation |
|---|---|---|
| Fixed dense schedule around expected phases | Provides direct observations across a broad peak window and supports comparisons at matched times. | Can impose substantial sampling burden, and a peak outside the expected window may still be missed. |
| Model-informed targeted schedule | Uses existing pharmacokinetic knowledge to place samples where the profile is expected to change most. | Depends on the model and assumptions being relevant to the study population, dose, formulation, and DDI condition. |
| Evenly spaced samples throughout follow-up | Simple to plan and may cover the overall time range. | May waste samples in slowly changing regions while leaving rapid early changes or the peak poorly covered. |
A sampling plan cannot remove uncertainty about the unobserved parts of a profile. A measured maximum is the largest concentration among collected samples; if the true peak occurs between samples, the observed maximum may be lower. Likewise, the information available for AUC depends on where samples occur and on the estimation approach used. Schedule selection is therefore one component of endpoint quality, not a substitute for appropriate analysis.
Common mistake: “The oral peak is predicted at 1.5 hours, so a single 1.5-hour sample is sufficient for \(C_{\max}\).” This reasoning treats a predicted time as exact and ignores shifts due to subject variability or the perpetrator. Instead, sample on both sides of the expected peak and cover a plausible range in each condition. For IV infusions, a related error is calling a 0.25-hour draw the end of a 30-minute infusion; 0.25 hours is 15 minutes, whereas the infusion ends at 0.5 hours.
Check Your Understanding
Answer each question, then compare your reasoning with the solutions.
- A 45-minute infusion starts at time zero. At what time in hours does it end, and is a 0.5-hour sample during or after the infusion?
- An oral probe may peak between 1 and 3 hours in a DDI study. Why is sampling only at 2 hours a weak plan?
- A probe has an estimated terminal half-life of 8 hours. Under a first-order terminal-phase assumption, what fraction remains after 32 hours from the start of that phase?
- Why should planned sample times generally be comparable in control and perpetrator conditions, even if the perpetrator may shift the peak?
Solutions. (1) \(45/60=0.75\) hours, so a 0.5-hour sample is during the infusion. (2) The peak could occur before or after 2 hours, and one draw provides no observations bracketing the plausible peak window; closer samples across 1–3 hours are more informative. (3) \(32/8=4\) half-lives, so the remaining fraction is \(2^{-4}=1/16=0.0625\), or 6.25%, under the stated assumption. (4) Matched nominal times make the profiles comparable relative to administration; covering a broad plausible window helps ensure that a timing shift is observed rather than concealed by a schedule tailored to only one condition.